Dudediligence.

Kyntra Bio, Inc

KYNBNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$123,000Sep ’24$3.1MDec ’24$2.7MMar ’25$1.3MJun ’25$1.1MSep ’25$1.3MDec ’25$3.7MMar ’26−$1.5MJun ’26
Net income, by quarter
−$17.1MSep ’24$18.0MDec ’24$4.6MMar ’25−$7.6MJun ’25$200.6MSep ’25−$14.2MDec ’25−$15.2MMar ’26$12.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$235.3M$140.7M$46.8M$29.6M$6.4M
Gross profit$222.4M$120.5M$42.8M$14.1M$5.9M
Operating income−$288.5M−$301.0M−$322.7M−$150.4M−$45.9M
Net income−$290.0M−$293.7M−$284.2M−$47.6M$183.5M
Operating cash flow−$82.2M−$145.9M−$315.0M−$138.0M−$4.8M
Free cash flow−$87.4M−$149.7M−$317.5M−$138.3M−$4.8M
Cash$171.2M$155.7M$81.6M$50.5M$47.9M
Shares outstanding92.9M94.2M98.8M4.0M4.0M